Top segments and regional performance

Last year, the company generated ‪2.87 B‬ EUR, the most of which — ‪2.76 B‬ EUR — came from its top-performing segment, Immunotherapy Technologies, compared to ‪2.87 B‬ EUR the previous year. The greatest contribution came from United States, which accounted for ‪1.72 B‬ EUR last year, with ‪1.93 B‬ EUR the year before.